MedNet Solutions Deploys Global Peripheral T-cell Lymphoma Registry for Allos Therapeutics
11 2월 2010 - 3:25AM
PR Newswire (US)
MINNETONKA, Minn., Feb. 10 /PRNewswire/ -- MedNet Solutions, a
global life sciences technology solutions company specializing in
clinical study management systems, is pleased to announce that
Allos Therapeutics' new international disease-specific registry for
patients with peripheral T-cell lymphoma (PTCL) has enrolled its
first study participant. This individual was enrolled Friday,
February 5th by Dr. Haluk Tezcan at the Kootenia Cancer Center in
Post Falls, ID. The registry, named COMPLETE (Comprehensive
Oncology Measures for Peripheral T-cell Lymphoma Treatment), was
built using ENLIGHTEN®, MedNet's industry-leading EDC/eClinical
technology solution. This represents the 5th disease-specific
registry built and deployed by MedNet Solutions within the last two
years. "We saw the importance of developing a global PTCL-specific
registry that addresses the urgent need to better understand the
real-world disease management across multiple treatment regimens,
such as drug therapy, stem cell transplant and radiation therapy,"
stated Dvorit Samid, Ph.D., vice president, Medical Affairs at
Allos Therapeutics. "MedNet has done an excellent job of initiating
the registry and meeting critical timelines. They worked closely
with a group of prominent international multi-disciplinary experts,
serving as a steering committee, to develop this new PTCL registry
- named COMPLETE - to prospectively study treatment patterns and
patient outcomes. We are committed to this important initiative and
believe that the data obtained will eventually help practitioners
optimize treatment for patients with aggressive PTCL." The COMPLETE
registry is a global 5 year observational study that will enroll
newly-diagnosed PTCL patients and collect data on longitudinal
treatment patterns and outcomes. The approximately 75 sites
expected to participate will represent academic, hospital and
community practices across the U.S. and Europe. "MedNet Solutions
is excited to work with Allos to build a registry that will help
the healthcare community increase their understanding of this
terrible disease," commented John M. (Rob) Robertson, president and
CEO of MedNet Solutions. "ENLIGHTEN will provide Allos with the
proven and efficient infrastructure needed to collect and analyze
treatment data and outcomes. About Allos Therapeutics Allos
Therapeutics, Inc. (NASDAQ:ALTH) is a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics. Allos is currently focused on the
development and commercialization of a folate analogue metabolic
inhibitor for hematologic malignancies and solid tumor indications.
Allos is headquartered in Westminster, CO. For additional
information, please visit http://www.allos.com/. About MedNet
Solutions MedNet Solutions is a leading healthcare technology
company specializing in clinical study management systems designed
for the global life sciences market. Applying critical insight,
proven technology and unwavering support, MedNet delivers powerful,
flexible and easy-to-use web-based solutions that support our
customers' clinical studies, registries and investigator initiated
trials. Since 2000, MedNet has successfully supported leading
pharmaceutical, medical device, and biotechnology organizations on
projects spanning 6 continents and more than 40 countries. MedNet
delivers a superior customer experience from beginning to end. For
more information, please visit http://www.mednetstudy.com/. Contact
Information: Dirk H. Nelson Marketing Manager 601 Carlson Parkway,
Suite 605 Minnetonka, MN 55305 USA (763) 258-2735 DATASOURCE:
MedNet Solutions CONTACT: Dirk H. Nelson, Marketing Manager of
MedNet Solutions, +1-763-258-2735 Web Site:
http://www.mednetstudy.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles